Van Dijk W, Mackiewicz A
Department of Medical Chemistry, Faculty of Medicine, Vrije Universiteit, Amsterdam, The Netherlands.
Ann N Y Acad Sci. 1995 Jul 21;762:319-30. doi: 10.1111/j.1749-6632.1995.tb32336.x.
The plasma levels and the glycosylation of acute-phase proteins (APP) are subject to marked changes during acute and chronic inflammation. The pathophysiological variations in different glycoforms of APP in serum most likely result from changes in the glycosylation process during their biosynthesis in the parenchymal cells of the liver. This is suggested from in vitro studies with isolated hepatocytes and hepatoma cell lines. Inflammatory cytokines appear to regulate the changes in glycosylation independent from the rate of synthesis of the APP. In addition, other humoral factors like corticosteroids and growth factors are involved. The interplay of these factors is determined by the stage of the disease (as in rheumatoid arthritis) or the physiological situation (as in pregnancy). The changes in glycosylation of specific APP might affect the operation of the immune system.
在急性和慢性炎症期间，急性期蛋白（APP）的血浆水平和糖基化会发生显著变化。血清中APP不同糖型的病理生理变化很可能是由于其在肝脏实质细胞生物合成过程中糖基化过程的改变所致。这是通过对分离的肝细胞和肝癌细胞系的体外研究得出的结论。炎性细胞因子似乎独立于APP的合成速率来调节糖基化的变化。此外，还涉及其他体液因子，如皮质类固醇和生长因子。这些因素的相互作用取决于疾病的阶段（如类风湿性关节炎）或生理状况（如妊娠）。特定APP糖基化的变化可能会影响免疫系统的运作。
